Annovis Bio Valuation
| ANVS Stock | USD 4.87 0.02 0.41% |
At this time, the firm appears to be undervalued. Annovis Bio shows a prevailing Real Value of $12.58 per share. The current price of the firm is $4.87. Our model approximates the value of Annovis Bio from analyzing the firm fundamentals such as Current Valuation of 54.56 M, return on equity of -5.97, and Shares Owned By Insiders of 20.40 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Annovis Bio's price fluctuation is somewhat reliable at this time. Calculation of the real value of Annovis Bio is based on 3 months time horizon. Increasing Annovis Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Annovis stock is determined by what a typical buyer is willing to pay for full or partial control of Annovis Bio. Since Annovis Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Annovis Stock. However, Annovis Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.87 | Real 12.58 | Hype 4.9 | Naive 4.41 |
The intrinsic value of Annovis Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Annovis Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Annovis Bio helps investors to forecast how Annovis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Annovis Bio more accurately as focusing exclusively on Annovis Bio's fundamentals will not take into account other important factors: Annovis Bio Total Value Analysis
Annovis Bio is presently anticipated to have valuation of 54.56 M with market capitalization of 67.19 M, debt of 17.96 M, and cash on hands of 35.97 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Annovis Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
54.56 M | 67.19 M | 17.96 M | 35.97 M |
Annovis Bio Asset Utilization
One of the ways to look at asset utilization of Annovis is to check how much profit was generated for every dollar of assets it reports. Annovis Bio shows a negative utilization of assets of -1.55 percent, losing $0.0155 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Annovis Bio shows how discouraging it operates for each dollar spent on its assets.Annovis Bio Ownership Allocation
The market capitalization of Annovis Bio is $67.19 Million. Annovis Bio retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Annovis Bio Profitability Analysis
Net Loss for the year was (56.2 M) with profit before overhead, payroll, taxes, and interest of 0.About Annovis Bio Valuation
The stock valuation mechanism determines Annovis Bio's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Annovis Bio based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Annovis Bio. We calculate exposure to Annovis Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Annovis Bio's related companies.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people.
Annovis Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Annovis Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 9 M |
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.